Aspire Biopharma Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASBP research report →
About the company
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management.
- CEO
- Kraig T. Higginson
- IPO
- 2025
- Employees
- 2
- HQ
- Estero, FL, US
Price Chart
- Market Cap
- $716.46K
- P/E
- -0.79
- P/S
- 20.73
- P/B
- 2.40
- EV/EBITDA
- -1.08
- Div Yield
- 0.00%
- Gross Margin
- 16.30%
- Op Margin
- -15745.85%
- Net Margin
- -34039.68%
- ROE
- 199.43%
- ROIC
- -121.89%
- Revenue
- $6.20K · 0.00%
- Net Income
- $-24,480,848 · -95.27%
- EPS
- $-16.38 · 9.85%
- Op Income
- $-19,351,291
- FCF YoY
- -1756.62%
- 52W High
- $35.00
- 52W Low
- $0.11
- 50D MA
- $4.37
- 200D MA
- $5.21
- Beta
- 0.16
- Avg Volume
- 13.34M
Get TickerSpark's AI analysis on ASBP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 5, 25 | Fell Donald G. | buy | 10,500 |
| Jun 4, 25 | Fell Donald G. | buy | 9,500 |
| Jun 5, 25 | Fell Donald G. | buy | 10,500 |
| Jun 4, 25 | Fell Donald G. | buy | 9,500 |
| Aug 18, 23 | AJJARAPU SURENDRA K | other | 0 |
| Aug 18, 23 | AJJARAPU SURENDRA K | other | 6,834,333 |
| Aug 18, 23 | Doshi Mayur Mansukhlal | other | 0 |
| Aug 18, 23 | Wadhwani Avinash R | other | 0 |
| Aug 18, 23 | PETERSON MICHAEL L | other | 0 |
| Aug 18, 23 | Fell Donald G. | other | 0 |
Our ASBP coverage
Recent articles, reports, and earnings notes.
No research on ASBP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ASBP report →Similar companies
Peers in the same neighborhood.